Zhou Jian, Wen Yang, Chen Xiangtian, Guo Linlang
Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Int J Gen Med. 2022 May 24;15:5181-5196. doi: 10.2147/IJGM.S355393. eCollection 2022.
Lung cancer is the most morbid and fatal cancer in the world, and nearly 85% of lung cancer is non-small cell lung cancer (NSCLC). Besides traditional chemotherapies, molecular targeted therapies and immunotherapies are increasing rapidly, but the treatment is still unsatisfactory. The study is to identify a new diagnostic and prognostic biomarker.
Data including mRNA expression and clinical information of lung adenocarcinoma (LUAD) patients were downloaded from The Cancer Genome Atlas (TCGA) database. Receiver operating characteristic (ROC) curve was constructed to assess the diagnostic value of syntrophin-γ2 (SNTG2) expression and Kaplan-Meier (KM) survival curves were used to compare the survival disparities. The protein-protein interaction (PPI) network was analysed by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and the connections between SNTG2 and immune cell infiltration were found with Tumor Immunoassay Resource (TIMER). Genetic mutation in SNTG2 and its association with overall survival (OS) were evaluated by cBioPortal. The relationship between SNTG2 and methylation and its association with overall survival were evaluated by MethSurv. Chi square and Mann-Whitney tests were used for statistical analyses. Xiantao Academic Online Website was used for online analysis.
Our results revealed that SNTG2 mRNA expression was lower in LUAD tissues than in both adjacent and non-adjacent normal tissues and low SNTG2 mRNA expression was verified to be correlated with histological grade, clinical stage, first therapy outcome and poor overall survival of LUAD. Next, ROC curve revealed diagnostic and prognostic value of SNTG2 for LUAD patients. Moreover, SNTG2 presented correlation with immune cell infiltration and immune checkpoints. Then, we revealed CC chemokine ligand 14 (CCL14), a co-expression gene with SNTG2, which has consistent influence with SNTG2. Furthermore, hypomethylation was found to be associated with high SNTG2 expression.
We revealed a potential diagnostic and prognostic indicator in LUAD and analyzed its influence on immunotherapy.
肺癌是全球发病和致死率最高的癌症，近85%的肺癌为非小细胞肺癌（NSCLC）。除传统化疗外，分子靶向治疗和免疫治疗发展迅速，但治疗效果仍不尽人意。本研究旨在寻找一种新的诊断和预后生物标志物。
从癌症基因组图谱（TCGA）数据库下载肺腺癌（LUAD）患者的mRNA表达及临床信息数据。构建受试者工作特征（ROC）曲线评估肌养蛋白γ2（SNTG2）表达的诊断价值，采用Kaplan-Meier（KM）生存曲线比较生存差异。通过搜索相互作用基因/蛋白质的工具（STRING）分析蛋白质-蛋白质相互作用（PPI）网络，并利用肿瘤免疫分析资源（TIMER）发现SNTG2与免疫细胞浸润之间的联系。通过cBioPortal评估SNTG2的基因突变及其与总生存期（OS）的关联。利用MethSurv评估SNTG2与甲基化的关系及其与总生存期的关联。采用卡方检验和Mann-Whitney检验进行统计分析。使用仙桃学术在线网站进行在线分析。
我们的结果显示，LUAD组织中SNTG2 mRNA表达低于相邻和非相邻正常组织，且低SNTG2 mRNA表达与LUAD的组织学分级、临床分期、首次治疗结果及总生存期差相关。其次，ROC曲线显示SNTG2对LUAD患者具有诊断和预后价值。此外，SNTG2与免疫细胞浸润和免疫检查点相关。然后，我们发现CC趋化因子配体14（CCL14）是与SNTG2共表达的基因，其与SNTG2具有一致的影响。此外，发现低甲基化与高SNTG2表达相关。
我们揭示了LUAD中一种潜在的诊断和预后指标，并分析了其对免疫治疗的影响。
